Literature DB >> 19444819

Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma.

Linda Ravenna1, Patrizio Sale, Maura Di Vito, Andrea Russo, Luisa Salvatori, Marco Tafani, Emanuela Mari, Steno Sentinelli, Elisa Petrangeli, Michele Gallucci, Franco Di Silverio, Matteo A Russo.   

Abstract

BACKGROUND: Recent studies have underlined the role of tumor cells in the endogenous synthesis of pro-inflammatory molecules. We tested whether malignant progression in prostate cancer was associated with the activation of a phenotype typical of the innate immune system.
METHODS: The expression of a set of molecules involved in tissue inflammation and repair was measured by real-time PCR and Western blot analysis in prostate samples in the absence or slight presence of a detectable leukocyte infiltrate. Whole tumor and non-tumor samples were analyzed in addition to laser-capture microdissected tumor and host epithelium. Receptor for advanced glycation end products, purine receptor, inducible enzymes cyclooxygenase-2 and nitric oxide synthase-2, pentraxin-3 and growth-survival factor receptors such as epithelial growth factor and estrogen alpha and beta receptors were all studied.
RESULTS: A global survey approach showed an up-regulation in tumor samples of all of the studied genes, with the exception of ERbeta. A laser-capture microdissection approach highlighted over-expression of pro-inflammatory molecules in each tumor sample examined. Nuclear translocation of nuclear factor-kB subunit p65 was observed in tumor tissues.
CONCLUSIONS: These data support the evidence that molecules typical of the innate immune system, similar to that of activated leukocytes, are produced by prostate epithelial cells and that their expression is up-regulated in malignant cells. We suggest that the observed pro-inflammatory and repair process activation may represent an important molecular mechanism in the progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444819     DOI: 10.1002/pros.20966

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

Review 2.  Estrogen receptors in prostate development and cancer.

Authors:  Chiuan-Ren Yeh; Jun Da; Wenbin Song; Anees Fazili; Shuyuan Yeh
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

Review 3.  Pathogen recognition by the long pentraxin PTX3.

Authors:  Federica Moalli; Sebastien Jaillon; Antonio Inforzato; Marina Sironi; Barbara Bottazzi; Alberto Mantovani; Cecilia Garlanda
Journal:  J Biomed Biotechnol       Date:  2011-06-02

Review 4.  ATP-gated P2X7 receptor as a potential target for prostate cancer.

Authors:  Cuicui Qiao; Yiqing Tang; Qianqian Li; Xiaodi Zhu; Xiaoxiang Peng; Ronglan Zhao
Journal:  Hum Cell       Date:  2022-06-03       Impact factor: 4.374

5.  P2X7 Receptor Function in Bone-Related Cancer.

Authors:  Elena Adinolfi; Francesca Amoroso; Anna Lisa Giuliani
Journal:  J Osteoporos       Date:  2012-08-16

6.  Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma.

Authors:  Marco Tafani; Maura Di Vito; Alessandro Frati; Laura Pellegrini; Elena De Santis; Giovanni Sette; Adriana Eramo; Patrizio Sale; Emanuela Mari; Antonio Santoro; Antonino Raco; Maurizio Salvati; Ruggero De Maria; Matteo A Russo
Journal:  J Neuroinflammation       Date:  2011-04-13       Impact factor: 8.322

7.  PTX3 gene activation in EGF-induced head and neck cancer cell metastasis.

Authors:  Wei-Chiao Chang; Shuo-Lun Wu; Wan-Chen Huang; Jinn-Yuan Hsu; Shih-Hung Chan; Ju-Ming Wang; Jhih-Peng Tsai; Ben-Kuen Chen
Journal:  Oncotarget       Date:  2015-04-10

8.  Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.

Authors:  S Kondo; H Ueno; H Hosoi; J Hashimoto; C Morizane; F Koizumi; K Tamura; T Okusaka
Journal:  Br J Cancer       Date:  2013-07-04       Impact factor: 7.640

9.  Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function.

Authors:  Bongkun Choi; Eun-Jin Lee; Da-Hyun Song; Sung-Chul Yoon; Yeon-Ho Chung; Youngsaeng Jang; Sang-Min Kim; Youngsup Song; Sang-Wook Kang; Seung-Yong Yoon; Eun-Ju Chang
Journal:  Oncotarget       Date:  2014-01-30

10.  Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis.

Authors:  Russell L Blaylock
Journal:  Surg Neurol Int       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.